In prostate cancer, a number of Wnt ligands were found to be upregulated in patient tumors and/or circulating tumor cells (CTCs), including non-canonical Wnt ligands (Wnt5a, Wnt7b, and Wnt11) and Wnt/β-catenin ligands (Wnt16), reviewed in [28]. This evidence concerns the gene WNT11 and prostate cancer.